top of page
  • Recruiting

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Updated: Feb 5

  • GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125

  • NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma


MCARH125-MCARH109

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma


A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT05431608

Official Title: Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : June 24, 2022

Click here for details on ClinicalTrials.gov

 

GPRC5D-Targeted CAR T Cell MCARH109

Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109 (Code C176222)

Autologous Anti-GPRC5D CAR-T Cells MCARH109

Autologous Anti-GPRC5D-CAR-4-1BB-expressing T-cells MCARH109

Autologous GPRC5D-targeted CAR T Cells MCARH109

MCARH 109

MCARH-109

MCARH109


BCMA-Targeted CAR T Cell MCARH125

 

Biological: MCARH125

Biological: MCARH109

 

- New York: Memorial Sloan-Kettering Cancer Center New York

 

Location

United States, New York

 

RELATED GPRC5D POSTS


NCT04555551: Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma


NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS


NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia


NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

 

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma






Comments


Posts Archive
bottom of page